By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Ingredients A-Z > Dangerous/banned > DMHA / Octodrine

DMHA / Octodrine

GMJ
Last updated: 02/06/2026 18:42
By
Prof. Giorgi Pkhakadze
Share
8 Min Read
SHARE

Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD — GMJ Editorial Board

5 min read|1,018 words

What is DMHA / Octodrine?

DMHA (2-aminoisoheptane), also known as octodrine or by its trade name Octodrine, is a synthetic stimulant compound that has been used in dietary supplements marketed for weight loss and athletic performance enhancement. Originally developed as a nasal decongestant in the 1950s, DMHA is structurally similar to amphetamine and other banned stimulants like DMAA (1,3-dimethylamylamine).

DMHA belongs to a class of compounds known as aliphatic amines and acts as a central nervous system stimulant. While it has appeared in various pre-workout supplements and fat burners, DMHA is not approved by the FDA for use in dietary supplements and has been banned by the World Anti-Doping Agency (WADA) for competitive athletes.

Health benefits & uses

Limited evidence: The purported benefits of DMHA are primarily based on anecdotal reports and theoretical mechanisms rather than rigorous clinical studies. Manufacturers have claimed it may:

Submit Your Paper
GMJ_Submit_Banner
  • Increase energy and focus
  • Enhance athletic performance
  • Promote weight loss through appetite suppression
  • Improve mood and motivation

However, there is a notable absence of peer-reviewed clinical trials demonstrating these effects or establishing the safety profile of DMHA in humans. The limited available research consists primarily of case reports documenting adverse events rather than therapeutic benefits.

How it works

DMHA is believed to work by increasing levels of neurotransmitters in the brain, particularly dopamine and norepinephrine. As a sympathomimetic amine, it likely stimulates the release of these catecholamines while also inhibiting their reuptake, leading to increased alertness, energy, and potentially euphoric effects.

The compound may also stimulate the release of adrenaline (epinephrine), contributing to its stimulant effects on heart rate, blood pressure, and metabolic rate. These mechanisms are similar to those of amphetamines and other controlled stimulants, which explains both the desired effects and the serious safety concerns associated with DMHA use.

Dosage

There is no established safe or effective dosage for DMHA, as it is not approved for human consumption as a dietary supplement. The FDA has not recognized DMHA as safe, and there is no recommended daily allowance (RDA) or upper limit (UL) established by health authorities.

Products that have illegally contained DMHA have typically included doses ranging from 25-200mg, but these amounts are based on manufacturer decisions rather than scientific evidence of safety or efficacy. Healthcare providers strongly advise against using products containing DMHA due to the lack of safety data and regulatory approval.

Food sources

DMHA does not occur naturally in foods. It is a synthetic compound created in laboratories. Some manufacturers have falsely claimed that DMHA is naturally derived from sources like Juglans regia (English walnut) extract, but scientific analysis has not supported these claims. Any DMHA found in supplements is synthetically produced.

Consumers should be aware that products may list DMHA under various names including octodrine, 2-aminoisoheptane, 6-amino-2-methylheptane, or 1,5-dimethylhexylamine to obscure its presence in ingredient lists.

Safety & side effects

DMHA poses significant safety risks and has been associated with serious adverse events. Reported side effects include:

  • Rapid or irregular heartbeat (tachycardia, arrhythmias)
  • Elevated blood pressure
  • Chest pain
  • Shortness of breath
  • Anxiety, agitation, and panic attacks
  • Insomnia and sleep disturbances
  • Headaches and dizziness
  • Nausea and vomiting

More serious complications may include stroke, heart attack, and psychiatric episodes. The FDA has issued warning letters to companies selling products containing DMHA, citing safety concerns and illegal marketing practices.

Interactions

DMHA may interact dangerously with numerous medications and substances, including:

  • Blood pressure medications (may reduce effectiveness)
  • Antidepressants, particularly MAO inhibitors (risk of hypertensive crisis)
  • Other stimulants, including caffeine (amplified cardiovascular risks)
  • Blood thinners (potential for altered effects)
  • Diabetes medications (may affect blood sugar control)

The combination of DMHA with other stimulants found in pre-workout supplements can create particularly dangerous interactions, significantly increasing the risk of cardiovascular complications.

Who should be cautious

Given its dangerous nature and lack of approval, no one should use DMHA-containing products. However, certain populations face particularly high risks:

  • Individuals with cardiovascular disease or risk factors
  • People with high blood pressure
  • Those with mental health conditions, especially anxiety disorders
  • Pregnant and breastfeeding women
  • Individuals under 18 years of age
  • People taking any medications
  • Competitive athletes subject to drug testing

Frequently asked questions

Is DMHA legal in dietary supplements?

No, DMHA is not legal for use in dietary supplements in the United States. The FDA has determined that DMHA does not meet the definition of a dietary ingredient and has taken enforcement action against companies selling products containing this substance.

How can I tell if a supplement contains DMHA?

Check ingredient lists for DMHA, octodrine, 2-aminoisoheptane, or other alternative names. However, some products may not accurately list all ingredients, so purchasing supplements from reputable manufacturers with third-party testing is advisable.

What should I do if I’ve taken a product containing DMHA?

Discontinue use immediately and consult a healthcare provider, especially if you experience any cardiovascular symptoms, anxiety, or other concerning effects. Report adverse events to the FDA’s MedWatch program.

Are there safe alternatives to DMHA for energy and performance?

Yes, consider evidence-based alternatives like moderate caffeine intake, proper nutrition, adequate sleep, and established supplements like creatine monohydrate for performance enhancement, always under professional guidance.

Why do some supplements still contain DMHA despite being banned?

Some manufacturers operate illegally or in regulatory gray areas, particularly with online sales. The supplement industry has limited pre-market oversight, making post-market enforcement challenging for regulatory agencies.

Classification:

Typical dose: — · Studied up to: —

References

Authoritative profile & live regulatory status: DMHA / Octodrine on SupplementIndex →

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
UK Sets Minimum Age of 11 for Puberty Blocker Clinical Trial in Gender-Questioning Children

The UK has set a minimum age of 11 years for children…

Why Women Choose Freebirth: What Research Reveals About Unattended Childbirth

A growing number of women are choosing unattended childbirth, driven by desire…

The Optimal Height for Elite Soccer Players: What Sports Science Reveals

Elite soccer demonstrates position-specific height selection rather than universal stature advantage. Analysis…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Wild / Bitter Almond

By
Prof. Giorgi Pkhakadze
02/06/2026

Khat / Cathinone

By
Prof. Giorgi Pkhakadze
02/06/2026

Comfrey (oral)

By
Prof. Giorgi Pkhakadze
02/06/2026

Phenibut

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up